Biotech's Next Big Thing -- ASCO II
<I>TheStreet</I> senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
